Josh (on behalf of Steve)'s questions to Abcellera Biologics Inc (ABCL) leadership • Q1 2025
Question
An analyst named Josh from Stifel, on for Steve, asked if the ABCL635 development plan includes healthy volunteers first and what specific biomarkers will be used to measure target engagement. He also inquired about the PSMAxCD3 T-Cell engager, asking about the preferred format, timeline for a development candidate, and the company's appetite for out-licensing versus internal development.
Answer
President and CEO Dr. Carl L. Hansen confirmed the ABCL635 trial will enroll healthy male and female volunteers in the early part, and the most reliable biomarker for target engagement will be testosterone levels. Regarding the T-cell engager (TCE) platform, he explained that the industry is still determining the optimal format for solid tumors and AbCellera is building tools to systematically investigate this. He stated that both internal development and out-licensing are options for TCE assets, with decisions made based on the specific opportunity.